| Literature DB >> 33312758 |
Yun Gu1, Yifan Chen2, Kaifeng Jin1, Yifan Cao3, Xin Liu1, Kunpeng Lv1, Xudong He1, Chao Lin3, Hao Liu3, He Li3, Hongyong He3, Jing Qin3, Ruochen Li3, Heng Zhang3, Weijuan Zhang2.
Abstract
Our previous study has identified intratumoral CD103+CD8+ T cells as a favorable prognostic factor in gastric cancer. However, the significance of CD103+CD4+ T cells in gastric cancer hasn't yet been elucidated. Here, we aimed to investigate the clinical significance and phenotype characteristics of intratumoral CD103+CD4+ T cells in gastric cancer. In our study, 469 formalin-fixed and paraffin-embedded samples and 24 fresh tissue specimens of patients with gastric cancer from Zhongshan Hospital were included. We manifested that intratumoral CD103+CD4+ T cells in gastric cancer predicted poor overall survival and inferior responsiveness to fluorouracil-based ACT. The density and phenotypic characteristics of CD103+CD4+ T cells in gastric cancer were detected by immunohistochemistry and flow cytometry, which showed that CD103+CD4+ T cells exhibited an immunosuppressive phenotype and higher retention capacity in tumor tissues. Furthermore, increased CD103+CD4+ T cells contributed to CD8+T cell dysfunction with decreased granzyme B (GZMB), interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α) and perforin (PRF-1) expression in gastric cancer. Overall, this study revealed that intratumoral CD103+CD4+T cell infiltration defined immunoevasive contexture and predicted poor prognosis and inferior responsiveness to fluorouracil-based ACT. Therefore, we recommended that CD103+CD4+ T cells might be a potential immunotherapeutic target for gastric cancer.Entities:
Keywords: CD103+CD4+ T cell; Gastric cancer; adjuvant therapy; prognosis
Mesh:
Substances:
Year: 2020 PMID: 33312758 PMCID: PMC7714530 DOI: 10.1080/2162402X.2020.1844402
Source DB: PubMed Journal: Oncoimmunology ISSN: 2162-4011 Impact factor: 8.110
Figure 1.CD103+CD4+ T cells accumulate in gastric cancer and associates tumor progression. (a) Representative immunofluorescence staining with CD4(green), CD103 (red) and DAPI (blue) in gastric cancer tissues. (b) Representative dual immunohistochemical staining images(left) for CD4(blue) and CD103(brown) and quantitative analysis(right) of CD103+CD4+ T cells in intratumoral tissues (n = 469) and corresponding peritumoral tissues (n = 469). Significance was assessed by unpaired t test. (c) Representative flow cytometry (FCM) analysis images (left) and quantification (right) of CD103+CD4+ T cells in CD3+ cells in intratumoral tissues and corresponding peritumoral tissues of gastric cancer fresh samples (n = 14). Significance was assessed by Wilcoxon matched-pairs signed-ranks test. (d) Relationship between intratumoral CD103+CD4+ T cells infiltration and TNM stage was examined based on IHC staining. Significance was assessed by unpaired t test. Bar plots show mean ± SD
Figure 2.Intratumoral CD103+CD4+ T cells predict poor prognosis in gastric cancer patients. (a and b) Kaplan–Meier survival curves for overall survival of gastric cancer patients in Discovery cohort(a) and Validation cohort(b) on the basis of intratumoral CD103+CD4+ T cell infiltration. (c and d) Kaplan–Meier survival curves for overall survival of gastric cancer patients in Discovery cohort(c) and Validation cohort(d) on the basis of intratumoral total CD4+ T cell infiltration. (e and f) Kaplan-Meier survival curves for overall survival of gastric cancer patients in the Discovery cohort (e) and Validation cohort (f) further stratified on the basis of CD103+CD4+ T cells in the total CD4+ T cell strata
Figure 3.Intratumoral CD103+CD4+ T cells indicate inferior responsiveness to fluorouracil-based adjuvant chemotherapy in stage II/III patients. (a andb) Kaplan-Meier survival curves for overall survival of gastric cancer patients with low CD103+CD4+ T cell infiltration in Discovery cohort (a) and Validation cohort (b) on the basis of ACT therapy. (c and d) Kaplan-Meier survival curves for overall survival of gastric cancer patients with high CD103+CD4+ T cell infiltration in Discovery cohort (c) and Validation cohort (d) on the basis of ACT therapy
Figure 4.Intratumoral CD103+CD4+ T cells express high level of IL-10 and display features of tissue residency. (a) Flow cytometry analysis of Th1 type cytokines (IFN-γ, TNF-α) in CD103−CD4+ and CD103+CD4+ T cells from gastric cancer tissues (n = 17,24). (b) Flow cytometry analysis of Th2 type cytokine IL-13 in CD103−CD4+ and CD103+CD4+ T cells from gastric cancer tissues (n = 24). (c) Flow cytometry analysis of Th17 type cytokine IL-17A in CD103−CD4+ and CD103+CD4+ T cells from gastric cancer tissues (n = 24). (d) Flow cytometry analysis of Treg type cytokines (IL-10, TGF-β1) in CD103−CD4+ and CD103+CD4+ T cells from gastric cancer tissues (n = 24). (e) Flow cytometry analysis of tissue egression markers (CCR7 and CD62L) and transcriptional factors (Blimp-1, Hobit, Runx-3 and TCF-1) in CD103−CD4+ and CD103+CD4+ T cells from gastric cancer tissues(n = 16,16,16,16,16,5). Significance was assessed by paired t test
Figure 5.Intratumoral CD103+CD4+ T cells are associated with impaired anti-tumor immunity by CD8+ T cells. (a) Numbers of CD8+ T cells in tissue microarray samples from patients with low and high CD103+CD4+ T cell infiltration. Significance was assessed by unpaired t test. (b) Ki67 expression of CD8+ T cells in gastric cancer tissue samples from patients with low(n = 9) and high(n = 9) CD103+CD4+ T cell infiltration. Significance was assessed by unpaired t test. (c and d) Cytolytic markers expression (PRF-1 and GZMB) of CD8+ T cells in gastric cancer tissue samples from patients with low(n = 9) and high(n = 9) CD103+CD4+ T cell infiltration. Significance was assessed by unpaired t test(c) and Mann Whitney U test(d). (e and f) Effector cytokines expression (TNF-α and IFN-γ) of CD8+ T cells in gastric cancer tissue samples from patients with low(n = 9) and high(n = 9) CD103+CD4+ T cell infiltration. Significance was assessed by Mann Whitney U test(e) and unpaired t test(f). Bar plots show mean ± SD